Salivary Gland Squamous Cell Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A squamous cell carcinoma arising from the salivary glands. The majority of patients are in their sixth through eight decades. It usually presents as a rapidly enlarging mass, which may be painful. It usually has an aggressive clinical course. 
There is 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains salivary gland squamous cell carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for salivary gland squamous cell carcinoma clinical trials .
Nanoparticle-based paclitaxel suspension and trastuzumab are the most common interventions in salivary gland squamous cell carcinoma clinical trials.
Significant Genes in Salivary Gland Squamous Cell Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for salivary gland squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and salivary gland squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.